Transgene Biotek [TRABI] vs Panacea Biotec [PANACEABIO] Detailed Stock Comparison
Transgene Biotek
BSE
Loading...
Panacea Biotec
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Transgene Biotek wins in 6 metrics, Panacea Biotec wins in 12 metrics, with 0 ties. Panacea Biotec appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Transgene Biotek | Panacea Biotec | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -48.67 | 229.89 | Transgene Biotek |
| Price-to-Book Ratio | 3.04 | 3.17 | Transgene Biotek |
| Debt-to-Equity Ratio | 144.77 | 2.67 | Panacea Biotec |
| PEG Ratio | 0.16 | -1.83 | Panacea Biotec |
| EV/EBITDA | -47.44 | -194.49 | Panacea Biotec |
| Profit Margin (TTM) | 100.00% | 1.88% | Transgene Biotek |
| Operating Margin (TTM) | -380.20% | -5.74% | Panacea Biotec |
| Return on Equity | -6.74% | -1.01% | Panacea Biotec |
| Return on Assets (TTM) | -0.47% | -0.65% | Transgene Biotek |
| Free Cash Flow (TTM) | $-5.04M | $-776.80M | Transgene Biotek |
| 1-Year Return | -43.99% | 46.26% | Panacea Biotec |
| Price-to-Sales Ratio (TTM) | 116.70 | 4.36 | Panacea Biotec |
| Enterprise Value | $415.59M | $25.74B | Panacea Biotec |
| EV/Revenue Ratio | 159.23 | 4.22 | Panacea Biotec |
| Gross Profit Margin (TTM) | 100.00% | 53.68% | Transgene Biotek |
| Revenue per Share (TTM) | $0 | $100 | Panacea Biotec |
| Earnings per Share (Diluted) | $-0.18 | $1.89 | Panacea Biotec |
| Beta (Stock Volatility) | 0.80 | 0.36 | Panacea Biotec |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Transgene Biotek vs Panacea Biotec Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Transgene Biotek | -9.82% | 14.66% | -1.13% | 1.86% | 14.06% | -28.78% |
| Panacea Biotec | -2.93% | 7.79% | 12.52% | 5.04% | 17.28% | 4.53% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Transgene Biotek | -43.99% | 36.45% | -0.45% | 48.98% | -91.63% | -95.45% |
| Panacea Biotec | 46.26% | 236.43% | 135.83% | 251.36% | 134.15% | 58.11% |
News Based Sentiment: Transgene Biotek vs Panacea Biotec
Transgene Biotek
News based Sentiment: NEGATIVE
The initiation of insolvency proceedings is a game-changing event for Transgene Biotek Ltd., significantly increasing the risk for investors. Coupled with consistent losses and a declining market cap, the company faces a very uncertain future, making this a critical month for its investment story.
Panacea Biotec
News based Sentiment: POSITIVE
Panacea Biotec demonstrated a strong month with a new UNICEF contract, a significant financial turnaround, and adherence to corporate governance standards. While a slight stock price decrease and previous bearish sentiment temper enthusiasm, the overall narrative is positive, indicating a potential recovery trajectory for the company.
Performance & Financial Health Analysis: Transgene Biotek vs Panacea Biotec
| Metric | TRABI | PANACEABIO |
|---|---|---|
| Market Information | ||
| Market Cap | ₹335.38M | ₹26.67B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 95,533 | 119,982 |
| 90 Day Avg. Volume | 53,167 | 196,384 |
| Last Close | ₹3.95 | ₹445.95 |
| 52 Week Range | ₹3.22 - ₹7.71 | ₹259.70 - ₹581.90 |
| % from 52W High | -48.77% | -23.36% |
| All-Time High | ₹322.50 (Jan 23, 2006) | ₹581.90 (Apr 28, 2025) |
| % from All-Time High | -98.78% | -23.36% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.00% | 0.44% |
| Quarterly Earnings Growth | 0.01% | 0.44% |
| Financial Health | ||
| Profit Margin (TTM) | 1.00% | 0.02% |
| Operating Margin (TTM) | -3.80% | -0.06% |
| Return on Equity (TTM) | -0.07% | -0.01% |
| Debt to Equity (MRQ) | 144.77 | 2.67 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹1.32 | ₹136.92 |
| Cash per Share (MRQ) | ₹0.04 | ₹17.95 |
| Operating Cash Flow (TTM) | ₹1.93M | ₹-1,547,900,000 |
| Levered Free Cash Flow (TTM) | ₹-6,761,000 | ₹-83,700,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Transgene Biotek vs Panacea Biotec
| Metric | TRABI | PANACEABIO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -48.67 | 229.89 |
| Forward P/E | N/A | N/A |
| PEG Ratio | 0.16 | -1.83 |
| Price to Sales (TTM) | 116.70 | 4.36 |
| Price to Book (MRQ) | 3.04 | 3.17 |
| Market Capitalization | ||
| Market Capitalization | ₹335.38M | ₹26.67B |
| Enterprise Value | ₹415.59M | ₹25.74B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 159.23 | 4.22 |
| Enterprise to EBITDA | -47.44 | -194.49 |
| Risk & Other Metrics | ||
| Beta | 0.80 | 0.36 |
| Book Value per Share (MRQ) | ₹1.32 | ₹136.92 |
Financial Statements Comparison: Transgene Biotek vs Panacea Biotec
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TRABI | PANACEABIO |
|---|---|---|
| Revenue/Sales | ₹765,000 | ₹1.33B |
| Cost of Goods Sold | ₹0 | ₹520.80M |
| Gross Profit | ₹765,000 | ₹804.50M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-5.66M | ₹-353.00M |
| EBITDA | ₹-4.98M | ₹-182.90M |
| Pre-Tax Income | ₹-7.13M | ₹-400,000 |
| Income Tax | ₹0 | ₹19.50M |
| Net Income (Profit) | ₹-7.13M | ₹-19.90M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TRABI | PANACEABIO |
|---|---|---|
| Cash & Equivalents | ₹2.84M | ₹821.30M |
| Total Current Assets | ₹12.64M | ₹5.45B |
| Total Current Liabilities | ₹127.38M | ₹3.67B |
| Long-Term Debt | ₹61.03M | ₹222.10M |
| Total Shareholders Equity | ₹100.30M | ₹8.31B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹32.85M | ₹5.43B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TRABI | PANACEABIO |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TRABI | PANACEABIO |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 95,533 | 119,982 |
| Average Daily Volume (90 Day) | 53,167 | 196,384 |
| Shares Outstanding | 75.77M | 61.25M |
| Float Shares | 48.28M | 15.45M |
| % Held by Insiders | 0.22% | 0.73% |
| % Held by Institutions | 0.00% | 0.00% |
Dividend Analysis & Yield Comparison: Transgene Biotek vs Panacea Biotec
| Metric | TRABI | PANACEABIO |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |